Search details
1.
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
J Pathol
; 250(1): 19-29, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31471895
2.
Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.
Lung Cancer
; 149: 84-89, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32980613
Results
1 -
2
de 2
1
Next >
>>